| 7:55 AM | Welcome & Introduction | Ron Waksman, MD (Speaker)
|
| 8:00 AM | DES Thrombosis | David J. Cohen, MD (Moderator) Donald E. Cutlip, MD (Moderator)
|
| 8:00 AM | Pathological Predictors of DES Thrombosis: Will Second Generation DES Reduce Stent Thrombosis? | Renu Virmani, MD (Speaker)
|
| 8:10 AM | Clinical Incidence and Predictors for Early and Late Stent Thrombosis: Lessons from the Clinical Trials | Donald E. Cutlip, MD (Speaker)
|
| 8:20 AM | OCT for the Longitudinal Evaluation of Vascular Healing Following DES Implantation: Will it be a Helpful Tool to Reduce Stent Thrombosis? | Juan F. Granada, MD (Speaker)
|
| 8:30 AM | Coronary Endothelial Dysfunction After DES: Presumed Mechanisms and Assessment Techniques. Are Next Generation DES Associated with Restored Coronary Vasomotion? | Aloke Finn, MD (Speaker)
|
| 8:40 AM | IVUS Predictors of Late Stent Thrombosis | Gary S. Mintz, MD (Speaker)
|
| 8:50 AM | Will Personalized Antiplatelet Therapy Reduce Stent Thrombosis? Emerging Drugs and Polymers | Paul A. Gurbel, MD (Speaker)
|
| 9:00 AM | How Should we Study the Optimal Duration of DAPT for the Prevention of DES Thrombosis? Update from the Ongoing Trials | Laura Mauri, MD (Speaker)
|
| 9:10 AM | Panel Discussion: What Else can be Done to Minimize Stent Thrombosis? | Donald E. Cutlip, MD (Moderator) Aloke Finn, MD (Panelist) Paul A. Gurbel, MD (Panelist) Laura Mauri, MD (Panelist) Gary S. Mintz, MD (Panelist)
|
| 9:25 AM | Industry Update: New DES Pipeline | Alexandre Abizaid, MD, PhD (Moderator) David E. Kandzari, MD (Moderator)
|
| 9:25 AM | The NEVO Program: Reservoir-based Sirolimus-eluting Stent | Campbell D. K. Rogers, MD (Speaker)
|
| 9:35 AM | Medtronic Non-polymeric DES Development | Josiah "Cy" N. Wilcox, PhD (Speaker)
|
| 9:45 AM | DES Development for the SFA | Gunnar Tepe, MD (Speaker)
|
| 9:55 AM | The XIENCE Program Update | Charles A. Simonton, MD (Speaker)
|
| 10:05 AM | The Next Generation BSC DES Program Update | Keith D Dawkins, MD (Speaker)
|
| 10:15 AM | Will DES Ever Work for SFA? | Lewis B. Schwartz, MD (Speaker)
|
| 10:25 AM | The OrbusNeich EP C-Coated Bioabsorbable Polymer Sirolimus-eluting Stent Program | Michael J. Kutryk, Other (Speaker)
|
| 10:35 AM | The BioFreedom Surface Etching Polymer-free DES System | John E. Shulze, MD (Speaker)
|
| 10:45 AM | The CardioMind SPARROW DES Program (CARE II): A Bioabsorbable Polymer Sirolimus-eluting “Micro-Stent" | Alexandre Abizaid, MD, PhD (Speaker)
|
| 10:55 AM | Are Polymer-free DES Systems Safer? Observations from Experimental Studies in Animal Models | Renu Virmani, MD (Speaker)
|
| 11:05 AM | One DES Eluting Two Drugs: Is it Feasible? | Robert Falotico, PhD (Speaker)
|
| 11:15 AM | The Catania™ Stent: New Data | Alessio La Manna, MD (Speaker)
|
| 11:25 AM | Degradation Kinetics: What are the Factors to Consider? | James P. Oberhauser, PhD (Speaker)
|
| 11:25 AM | Bioabsorbable Stent Symposium | Ron Waksman, MD (Moderator)
|
| 11:35 AM | Challenges with Biodegradable Stents | Syed Hossainy, PhD (Speaker)
|
| 11:45 AM | PLLA Based Biodegradable Stent for SFA | Renu Virmani, MD (Speaker)
|
| 11:55 AM | Update on the Development and Clinical Trials of Absorbable Magnesium Stents | Ron Waksman, MD (Speaker)
|
| 12:05 PM | Update on the BVS Development and Clinical Program | Richard J Rapoza, PhD (Speaker)
|
| 12:15 PM | The REVA Tyrosine-derived Polycarbonate Bioabsorbable Stent: Lessons Learned and Future Directions | Robert K Schultz, PhD (Speaker)
|
| 12:35 PM | Regulatory Challenges for Biodegradable Stent Approval |
|
| 12:45 PM | Panel Discussion: The Future of the Biodegradable Stent | Maurice Buchbinder, MD (Panelist) Bodo Cremers, MD (Panelist) Syed Hossainy, PhD (Panelist) James P. Oberhauser, PhD (Panelist) Richard J Rapoza, PhD (Panelist) Robert K Schultz, PhD (Panelist) Renu Virmani, MD (Panelist) Ron Waksman, MD (Moderator)
|
| 1:00 PM | Lunch & Visit the Exhibits |
|
| 2:00 PM | DES Head to Head Debates | Stephen G. Ellis, MD (Moderator) Spencer B. King, MD (Moderator)
|
| 2:01 PM | Debate: DES Should be Used for Over 75% of the PCIs - Pro | Gregg W. Stone, MD (Speaker)
|
| 2:08 PM | Debate: DES Should be Used for Over 75% of the PCIs - Con | Spencer B. King, MD (Speaker)
|
| 2:16 PM | Discussion | Spencer B. King, MD (Speaker) Gregg W. Stone, MD (Panelist)
|
| 2:20 PM | Debate: Xience vs Taxus - The Studies are Definitive | Charles A. Simonton, MD (Speaker)
|
| 2:28 PM | Debate: Xience vs Taxus - Not so Fast: The Studies are Problematic | Keith D Dawkins, MD (Speaker)
|
| 2:36 PM | Debate: Xience vs Taxus - Discussion | Keith D Dawkins, MD (Speaker) Charles A. Simonton, MD (Speaker)
|
| 2:40 PM | Unprotected Left Main: The Guidelines Should be Changed now- Pro | Jeffrey J. Popma, MD (Speaker)
|
| 2:48 PM | Unprotected Left Main: The Guidelines Should be Changed Now- Con | Jeff A. Brinker, MD (Speaker)
|
| 2:56 PM | Discussion | Jeff A. Brinker, MD (Speaker) Jeffrey J. Popma, MD (Speaker)
|
| 3:00 PM | What are the FDA Requirements for Label Expansion? | Ashley B. Boam, Other (Speaker)
|
| 3:10 PM | Refreshment Break |
|
| 3:25 PM | Remaining Challenges with DES | David J. Cohen, MD (Speaker) Jeffrey J. Popma, MD (Moderator)
|
| 3:25 PM | How did the SYNTAX Study Change my Practice? | David R. Holmes, MD (Speaker)
|
| 3:35 PM | Is There a DES That Works Better for Diabetes? | Aloke Finn, MD (Speaker)
|
| 3:45 PM | DES for the Diabetic Patient: Can we Make it Better? | Stephen G. Ellis, MD (Speaker)
|
| 3:55 PM | DES for In-stent Restenosis: Is There an Optimal Therapy? | Ron Waksman, MD (Speaker)
|
| 4:15 PM | Will we Ever see a Dedicated Bifurcated DES in Clinical Practice? | Aaron V. Kaplan, MD (Speaker)
|
| 4:25 PM | The Drug Eluting Balloon Symposium | Bodo Cremers, MD (Moderator) Juan F. Granada, MD (Moderator) Ron Waksman, MD (Moderator)
|
| 4:25 PM | How Drug Eluting Balloons Work: The Preclinical Data | Robert S. Schwartz, MD (Speaker)
|
| 4:35 PM | Translational Approaches to Drug Eluting Balloon Evaluation: How to Prove Safety and Efficacy | Juan F. Granada, MD (Speaker)
|
| 4:45 PM | The BRAUN Paclitaxel-eluting Balloon Program: Experimental Findings and Clinical Outcomes of the PEPCAD Trials | Martin Unverdorben, Other (Speaker)
|
| 4:55 PM | Drug Eluting Balloons for Endovascular Applications: THUNDER Trial and Others | Gunnar Tepe, MD (Speaker)
|
| 5:05 PM | Regulatory Requirements for Drug Eluting Balloons |
|
| 5:15 PM | The Invatec Program: Features and Clinical Trials | Bruno Scheller, Other (Speaker)
|
| 5:25 PM | Second Generation DIOR DEB | Rembert Pogge Von Strandmann, PhD (Speaker)
|
| 5:35 PM | The Eurocor Drug Eluting Balloon System Design and Clinical Update: The Valentines Study | Olivier F. Bertrand, MD, PhD (Speaker)
|
| 5:45 PM | Panel Discussion: Will Drug Eluting Balloons Play a Role in Interventional Cardiology? If so, to Which Application? | Olivier F. Bertrand, MD, PhD (Panelist) Giuseppe Biondi Zoccai, MD (Panelist) Bodo Cremers, MD (Panelist) Juan F. Granada, MD (Speaker) Robert S. Schwartz, MD (Moderator) Gunnar Tepe, MD (Panelist) Martin Unverdorben, Other (Panelist)
|
| 6:05 PM | Adjourn |
|